Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16441718 | 0.85 | FBP1 (0.40) | FBP1KDM4EKMT2APYCR1EGFR | |
| SCHEMBL4003975 | 0.85 | PTGDR2 (0.43) | FBP1KDM4EKMT2APYCR1HPGD | |
| SCHEMBL3235607 | 0.84 | HPGD (0.50) | KDM4EKMT2AEGFRHPGDALDH1A1 | |
| SCHEMBL31053304 | 0.82 | FBP1 (0.44) | FBP1KDM4EKMT2AHPGDSLC6A4 | |
| SCHEMBL1516692 | 0.82 | FBP1 (0.44) | FBP1KDM4EKMT2AHPGDSLC6A4 | |
| SCHEMBL23861111 | 0.80 | SLC6A4 (0.51) | FBP1KDM4EKMT2AHPGDSLC6A4 | |
| SCHEMBL30058019 | 0.80 | SLC6A4 (0.51) | FBP1KDM4EKMT2AHPGDSLC6A4 | |
| SCHEMBL8591832 | 0.80 | SLC6A4 (0.40) | KDM4EKMT2ASLC6A4ALDH1A1NPC1 | |
| SCHEMBL1125103 | 0.80 | PYCR1 (0.53) | KDM4EKMT2APYCR1TDP1ALDH1A1 | |
| SCHEMBL30423333 | 0.80 | PYCR1 (0.53) | KDM4EKMT2APYCR1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-1097141-B1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | disclosed |
| US-6369236-B1 | DRUG FOR MEDICAL DIAGNOSIS ANTIARRHYTHMIC PROPRIETIES AND CONTAIN A CARDIOPROTECTIVE COMPOUND. THEY CAN PREVENTIVELY INHIBIT OR STRONGLY REDUCE PATHOPHYSIOLOGIC PROCESSES UPON OCCURRENCE OF ISCHEMIC INJURIES, ESPECIALLY ISCHEMIC CARDIAC | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-1097141-A1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | Aventis Pharma Deutschland GmbH (DE) | 2001-05-09 | — | — | EP | disclosed |
| EP-1053224-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000003996-A1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999040064-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-08-12 | — | — | WO | disclosed |